Altered sphingolipid metabolism in human endometrial cancer

Prostaglandins and Other Lipid Mediators

Volumn 92, Issue 1-4, 2010, Pages 62-66

  Knapp, Paweł ^a   Baranowski, Marcin ^a   Knapp, Małgorzata ^a   Zabielski, Piotr ^a   Błachnio Zabielska, Agnieszka U ^a   Górski, Jan ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Ceramide S1P rheostat; Endometrioid carcinoma; SPHK; SPT; Tumor

Indexed keywords

CERAMIDE; DIHYDROCERAMIDE; SERINE PALMITOYLTRANSFERASE; SPHINGANINE; SPHINGOLIPID; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIPID METABOLISM; MYOMA; UPREGULATION;

CASE-CONTROL STUDIES; CERAMIDES; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SERINE C-PALMITOYLTRANSFERASE; SPHINGOLIPIDS;

EID: 77952109192     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.03.002     Document Type: Article

References (35)

1. Saddoughi S.A., Song P., and Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 49 (2008) 413-440
2. Bartke N., and Hannun Y.A. Bioactive sphingolipids: metabolism and function. J Lipid Res 50 Suppl. (2009) S91-S96
3. Segui B., Andrieu-Abadie N., Jaffrezou J.P., Benoist H., and Levade T. Sphingolipids as modulators of cancer cell death: potential therapeutic targets. Biochim Biophys Acta 1758 (2006) 2104-2120
4. Xia P., Gamble J.R., Wang L., et al. An oncogenic role of sphingosine kinase. Curr Biol 10 (2000) 1527-1530
5. French K.J., Upson J.J., Keller S.N., Zhuang Y., Yun J.K., and Smith C.D. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 318 (2006) 596-603
6. Selzner M., Bielawska A., Morse M.A., et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 61 (2001) 1233-1240
7. Karahatay S., Thomas K., Koybasi S., et al. Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett 256 (2007) 101-111
8. Schiffmann S., Sandner J., Birod K., et al. Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 30 (2009) 745-752
9. Koyanagi S., Kuga M., Soeda S., et al. Elevation of de novo ceramide synthesis in tumor masses and the role of microsomal dihydroceramide synthase. Int J Cancer 105 (2003) 1-6
10. Chaudhry P., and Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer 16 (2009) 363-380
11. Engelsen I.B., Akslen L.A., and Salvesen H.B. Biologic markers in endometrial cancer treatment. APMIS 117 (2009) 693-707
12. Baranowski M., Zabielski P., Blachnio A., and Gorski J. Effect of exercise duration on ceramide metabolism in the rat heart. Acta Physiol (Oxf) 192 (2008) 519-529
13. Merrill Jr. A.H. Characterization of serine palmitoyltransferase activity in Chinese hamster ovary cells. Biochim Biophys Acta 754 (1983) 284-291
14. Vessey D.A., Kelley M., and Karliner J.S. A rapid radioassay for sphingosine kinase. Anal Biochem 337 (2005) 136-142
15. Liu H., Sugiura M., Nava V.E., et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 275 (2000) 19513-19520
16. Koybasi S., Senkal C.E., Sundararaj K., et al. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem 279 (2004) 44311-44319
17. Rylova S.N., Somova O.G., and Dyatlovitskaya E.V. Comparative investigation of sphingoid bases and fatty acids in ceramides and sphingomyelins from human ovarian malignant tumors and normal ovary. Biochemistry (Mosc) 63 (1998) 1057-1060
18. Williams R.D., Nixon D.W., and Merrill Jr. A.H. Comparison of serine palmitoyltransferase in Morris hepatoma 7777 and rat liver. Cancer Res 44 (1984) 1918-1923
19. Carton J.M., Uhlinger D.J., Batheja A.D., et al. Enhanced serine palmitoyltransferase expression in proliferating fibroblasts, transformed cell lines, and human tumors. J Histochem Cytochem 51 (2003) 715-726
20. Park J.H., and Schuchman E.H. Acid ceramidase and human disease. Biochim Biophys Acta 1758 (2006) 2133-2138
21. Kandyba A.G., Somova O.G., Kozlov A.M., et al. Sphingolipids of transplantable rat nephroma-RA. Biochemistry (Mosc) 65 (2000) 703-706
22. Riboni L., Campanella R., Bassi R., et al. Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 39 (2002) 105-113
23. Andreasian G.O., Malykh I.N., and Diatlovitskaia E.V. Ceramides and gangliosides in benign and malignant human ovarian tumors. Vopr Med Khim 42 (1996) 248-253
24. Vadas M., Xia P., McCaughan G., and Gamble J. The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction?. Biochim Biophys Acta 1781 (2008) 442-447
25. Shida D., Takabe K., Kapitonov D., Milstien S., Spiegel S., and Targeting. SphK1 as a new strategy against cancer. Curr Drug Targets 9 (2008) 662-673
26. Sutphen R., Xu Y., Wilbanks G.D., et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 1185-1191
27. Silins I., Nordstrand M., Hogberg J., and Stenius U. Sphingolipids suppress preneoplastic rat hepatocytes in vitro and in vivo. Carcinogenesis 24 (2003) 1077-1083
28. Ahn E.H., and Schroeder J.J. Sphinganine causes early activation of JNK and p38 MAPK and inhibition of AKT activation in HT-29 human colon cancer cells. Anticancer Res 26 (2006) 121-127
29. Wang H., Maurer B.J., Liu Y.Y., et al. N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol Cancer Ther 7 (2008) 2967-2976
30. Cinel L., Polat A., Aydin O., Dusmez D., and Egilmez R. Bcl-2, iNOS, p53 and PCNA expression in normal, disordered proliferative, hyperplastic and malignant endometrium. Pathol Int 52 (2002) 384-389
31. Miturski R., Semczuk A., Tomaszewski J., and Jakowicki J. Bcl-2 protein expression in endometrial carcinoma: the lack of correlation with p53. Cancer Lett 133 (1998) 63-69
32. Hogberg T. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Clin Oncol (R Coll Radiol) 20 (2008) 463-469
33. Min J., Mesika A., Sivaguru M., et al. (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol Cancer Res 5 (2007) 801-812
34. Noda S., Yoshimura S., Sawada M., et al. Role of ceramide during cisplatin-induced apoptosis in C6 glioma cells. J Neurooncol 52 (2001) 11-21
35. Rath G., Schneider C., Langlois B., et al. De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma. Int J Biochem Cell Biol 41 (2009) 1165-1172